OBJECTIVES: Recent studies have identified podoplanin, a mucin-type transmembrane glycoprotein, as a biomarker for oral cancer risk in patients with oral leukoplakia (OPL). The aim of this study was to investigate the potential association between podoplanin and the risk of malignant transformation of OPL with epithelial dysplasia. MATERIALS AND METHODS: In this retrospective study, podoplanin immunoexpression was analyzed in 58 patients with oral leukoplakia that showed epithelial dysplasia. Lesions with podoplanin expression in the basal and suprabasal layers of oral epithelium at one area or showing suprabasal expression at two or more areas were considered as positive. Association between podoplanin expression and oral cancer development was analyzed. RESULTS: Twenty-two of the 58 lesions (38%) were classified as podoplanin-positive, and the remaining 36 (62%) lesions were considered podoplanin-negative. The expression of podoplanin was correlated with the grade of dysplasia (p<0.0005), and with the risk of progression to oral cancer (p<0.0005). In multivariate survival analysis, only premalignant oral lesions displaying positive podoplanin expression showed a significantly increased risk of developing an oral squamous cell carcinoma (hazard ratio=8.738, p=0.007). CONCLUSION: Podoplanin could be a valuable biomarker for risk assessment of malignant transformation in patients with OPL along with histological assessment.
OBJECTIVES: Recent studies have identified podoplanin, a mucin-type transmembrane glycoprotein, as a biomarker for oral cancer risk in patients with oral leukoplakia (OPL). The aim of this study was to investigate the potential association between podoplanin and the risk of malignant transformation of OPL with epithelial dysplasia. MATERIALS AND METHODS: In this retrospective study, podoplanin immunoexpression was analyzed in 58 patients with oral leukoplakia that showed epithelial dysplasia. Lesions with podoplanin expression in the basal and suprabasal layers of oral epithelium at one area or showing suprabasal expression at two or more areas were considered as positive. Association between podoplanin expression and oral cancer development was analyzed. RESULTS: Twenty-two of the 58 lesions (38%) were classified as podoplanin-positive, and the remaining 36 (62%) lesions were considered podoplanin-negative. The expression of podoplanin was correlated with the grade of dysplasia (p<0.0005), and with the risk of progression to oral cancer (p<0.0005). In multivariate survival analysis, only premalignant oral lesions displaying positive podoplanin expression showed a significantly increased risk of developing an oral squamous cell carcinoma (hazard ratio=8.738, p=0.007). CONCLUSION:Podoplanin could be a valuable biomarker for risk assessment of malignant transformation in patients with OPL along with histological assessment.
Authors: Juan Carlos de Vicente; Tania Rodríguez Santamarta; Juan Pablo Rodrigo; Juana María García-Pedrero; Eva Allonca; Verónica Blanco-Lorenzo Journal: Virchows Arch Date: 2015-03-01 Impact factor: 4.064
Authors: Victor D Martinez; Calum E MacAulay; Martial Guillaud; Wan L Lam; Lewei Zhang; Kitty K Corbett; Miriam P Rosin Journal: Oral Oncol Date: 2014-09-16 Impact factor: 5.337
Authors: Nilva K Cervigne; Jerry Machado; Rashmi S Goswami; Bekim Sadikovic; Grace Bradley; Bayardo Perez-Ordonez; Natalie Naranjo Galloni; Ralph Gilbert; Patrick Gullane; Jonathan C Irish; Igor Jurisica; Patricia P Reis; Suzanne Kamel-Reid Journal: Hum Mol Genet Date: 2014-01-08 Impact factor: 6.150
Authors: Nicola Sgaramella; Eva Lindell Jonsson; Linda Boldrup; Luigi Califano; Philip J Coates; Gianpaolo Tartaro; Lorenzo Lo Muzio; Robin Fåhraeus; Giuseppe Colella; Giovanni Dell'Aversana Orabona; Lotta Loljung; Mario Santagata; Riccardo Rossiello; Torben Wilms; Karin Danielsson; Göran Laurell; Karin Nylander Journal: J Pathol Clin Res Date: 2015-10-09